Harvard Bioscience, Inc. (NASDAQ: HBIO) has filed an 8-K report with the Securities and Exchange Commission on March 17, 2026, detailing a corporate presentation aimed at providing updates to the investment community. The filing includes significant information regarding the company's operational performance and strategic direction. The presentation outlines the company's recent achievements, including the appointment of new executive leadership, with John Duke as CEO and Mark Frost as permanent CFO. The company has also successfully refinanced its debt, extending maturity to 2029 and generating annual cash savings of $3 million. This strategic move enhances financial flexibility to support long-term growth objectives. Furthermore, the report highlights a focus on consolidating operations, which is expected to yield approximately $3 million in adjusted EBITDA improvement by 2027. Harvard Bioscience is positioning itself as a leader in translational science tools, emphasizing its commitment to innovation and market leadership. The company reported $87 million in revenue for FY25, with a 58% adjusted gross margin and a strong recurring revenue model. The outlook for FY26 indicates revenue growth between 2% and 4%, with adjusted EBITDA growth projected between 6% and 10%. The corporate presentation, attached as Exhibit 99.1, provides further insights into the company's strategic initiatives and operational metrics, reinforcing its commitment to delivering value to shareholders and stakeholders alike.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.